TI
KYTX icon

Trexquant Investment’s Kyverna Therapeutics KYTX Stock Holding History

Trexquant Investment’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,109
Closed -$90.7K – 1984
2025
Q3 		$90.7K Buy
+15,109
New +$60.4K ﹤0.01% 1537

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Trexquant Investment's KYTX Position: Q4 2025 in Review

Trexquant Investment sold out of Kyverna Therapeutics (KYTX) in Q4 2025, closing a stake of 15,109 shares — an estimated $90.7K sold.

Trexquant Investment first reported a position in KYTX in Q3 2025 and held it in 1 quarter. The position peaked at $90.7K in Q3 2025. 99 funds tracked by Wall St. Rank hold KYTX as of Q4 2025.

  • Trexquant Investment reported no remaining Kyverna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Trexquant Investment sold 15,109 Kyverna Therapeutics shares in Q4 2025, an estimated $90.7K.
  • Trexquant Investment first reported a position in Kyverna Therapeutics in Q3 2025 and held it in 1 quarter.
  • Trexquant Investment's Kyverna Therapeutics position peaked at $90.7K in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.